Are Ozempic, Wegovy, and other GLP-1 receptor agonists linked to pancreatic cancer risk, and what does current evidence show in Europe?

GLP-1 receptor agonists and pancreatic cancer explained: semaglutide, liraglutide, tirzepatide, safety data, observational studies, and regulatory review.

In this episode, we review recent research evaluating whether GLP-1RA medications are associated with increased pancreatic cancer risk and how doctors interpret these findings under EU medical guidance.

You’ll learn:

• What GLP-1 receptor agonists are and how they work in diabetes and weight management

• Why earlier safety concerns emerged regarding pancreatitis and pancreatic cancer

• What recent large-scale studies report about cancer risk

• The difference between association, signal detect ...